In the sixth Preview relating to the annual meeting at #AACR17, we take a closer look at an immuno-oncology topic that we are likely to see and hear more about over the next couple of years.

Indeed, I’ve followed some cancer conferences where it wasn’t even mentioned, much to my surprise. It should be, it’s likely going to be both needed and receive a lot of attention over the next few years.

What we need is a bridge for greater success.  What does that look like though and how do we go about achieving it?

Subscribers can log-in to learn more

This content is restricted to subscribers

Posted by